Table 1.

Demographic background of participants at baseline completing CQR at both timepoints.

CharacteristicsParticipants Completing CQR Twice, TotalParticipants Taking Stable Antirheumatic Therapy Completing CQR Twice, SubgroupParticipants Undergoing Treatment Change and Completing CQR Twice, Subgroup
Patients, n786612
Sex, male/female (female %)18/60 (76.9)15/51 (77.3)3/9 (75.0)
Age, yrs, mean ± SD58.9 ± 11.958.9 ± 11.759.1 ± 13.7
Conventional DMARD therapies, n56479
Biologic DMARD, %
Glucocorticoids, %51.347.075.0
  • CQR: Compliance-Questionnaire-Rheumatology; DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; SSZ: sulfasalazine; LEF: leflunomide; HCQ: hydroxychloroquine; AZA: azathioprine.